Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.36 |
| ▸ | HTR3A | P46098 | 3/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL147113 | 0.78 | ALDH1A1 (0.39) | CYP1A2CYP2A6CHRNA7HTR3AALDH1A1 | |
| SCHEMBL19756688 | 0.75 | CHRNA7 (0.38) | CHRNA7HTR3AALDH1A1 | |
| SCHEMBL13893785 | 0.75 | CYP3A4 (0.41) | CHRNA7ALDH1A1LMNA | |
| SCHEMBL13885534 | 0.75 | CYP2A6 (0.34) | CYP2A6CHRNA7HTR3ALMNAAHR | |
| SCHEMBL2428854 | 0.75 | PSMB8 (0.36) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL23220879 | 0.75 | HDAC3 (0.54) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2092544 | 0.75 | HDAC3 (0.50) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL147267 | 0.75 | CHRNA7 (0.36) | CYP1A2CHRNA7HTR3AALDH1A1PARP1 | |
| SCHEMBL31125053 | 0.75 | HDAC3 (0.54) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL19134517 | 0.75 | ALOX5 (0.58) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11396505-B2 | Inhibitors of CaMKK2 and uses of same | NEW YORK UNIVERSITY (US) | 2022-07-26 | — | — | US | disclosed |
| WO-2021113698-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20200369656-A1 | INHIBITORS OF CAMKK2 AND USES OF SAME | NEW YORK UNIVERSITY | 2020-11-26 | — | — | US | disclosed |
| EP-3154973-B1 | TRICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-21 | — | — | EP | disclosed |
| US-9796713-B2 | Tricyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-24 | — | — | US | disclosed |
| US-9708323-B2 | Tricyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| US-20170137425-A1 | TRICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170129892-A1 | TRICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-11 | — | — | US | disclosed |
| WO-2015191403-A1 | TRICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-17 | — | — | WO | disclosed |
| WO-2015191401-A1 | TRICYCLIC COMPOUNDS AS ALPHA- 7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-17 | — | — | WO | disclosed |
| US-8637542-B2 | Kinase inhibitors and methods of use | INTELLIKINE, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8623407-B2 | Gabapentin-containing solid compositions and process for preparing the same | PFIZER INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623407-B2 | Gabapentin-containing solid compositions and process for preparing the same | PFIZER INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20090156677-A1 | Gabapentin-containing Solid Compositions and Process for Preparing the Same | PFIZER INC | 2009-06-18 | — | — | US | disclosed |
| US-20090156677-A1 | Gabapentin-containing Solid Compositions and Process for Preparing the Same | PFIZER INC | 2009-06-18 | — | — | US | disclosed |
| US-7309719-B1 | Storage stability; gabapentin and pregabalin, and neutral alpha -amino acid | WARNER LAMBERT COMPANY, LLC (US) | 2007-12-18 | — | — | US | disclosed |
| US-7309719-B1 | Storage stability; gabapentin and pregabalin, and neutral alpha -amino acid | WARNER LAMBERT COMPANY, LLC (US) | 2007-12-18 | — | — | US | disclosed |
| EP-1228066-A2 | SULFONAMIDE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001032646-A2 | SULFONAMIDE DERIVATIVES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11396505-B2 | Inhibitors of CaMKK2 and uses of same | CAMKK2, CAMKK1, CAMK1 | HDAC3 2784/4885HDAC4 2496/4885HDAC1 3137/4885 |
| US-20090156677-A1 | Gabapentin-containing Solid Compositions and Process for Preparing the Same | GABRD, GABRA6, GABRB1 | HDAC3 2305/4885HDAC4 2067/4885HDAC1 2469/4885 |
| US-20170129892-A1 | TRICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA6, CHRNA5 | HDAC3 389/4885HDAC4 1546/4885HDAC1 490/4885 |
| US-20200369656-A1 | INHIBITORS OF CAMKK2 AND USES OF SAME | CAMKK2, CAMKK1, CAMK1 | HDAC3 2784/4885HDAC4 2496/4885HDAC1 3137/4885 |
| US-20170137425-A1 | TRICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA6, CHRNA5 | HDAC3 462/4885HDAC4 1638/4885HDAC1 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.